Home » Stocks » ONCS

OncoSec Medical Incorporated (ONCS)

Stock Price: $7.18 USD -0.05 (-0.69%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 200.78M
Revenue (ttm) n/a
Net Income (ttm) -45.72M
Shares Out 26.77M
EPS (ttm) -2.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $7.18
Previous Close $7.23
Change ($) -0.05
Change (%) -0.69%
Day's Open 7.25
Day's Range 6.71 - 7.25
Day's Volume 216,490
52-Week Range 1.17 - 7.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 5 days ago

PENNINGTON, N.J. and SAN DIEGO, Jan. 20, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on designing, ...

PRNewsWire - 2 months ago

PENNINGTON, N.J. and SAN DIEGO, Nov. 24, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intra-tumor...

Seeking Alpha - 2 months ago

OncoSec has had very promising results in metastatic melanoma. It has also expanded its program in triple-negative breast cancer to now treat first-line patients.

PRNewsWire - 2 months ago

PENNINGTON, N.J. and SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced new positive interim data from its KEYNOTE-...

PRNewsWire - 3 months ago

PENNINGTON, N.J. and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intra-tumoral cancer imm...

PRNewsWire - 4 months ago

PENNINGTON, N.J. and SAN DIEGO, Aug.

PRNewsWire - 5 months ago

SAN DIEGO and PENNINGTON, N.J., Aug. 16, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that in connection with its previously an...

PRNewsWire - 5 months ago

SAN DIEGO and PENNINGTON, N.J., Aug. 14, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that it intends to offer and sell shares ...

PRNewsWire - 8 months ago

PENNINGTON, N.J. and SAN DIEGO, May 14, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, announced today t...

GuruFocus - 1 year ago

Markets soar on US-China trade talk optimism.

Other stocks mentioned: BBBY, PUMP, RARX
Seeking Alpha - 1 year ago

OncoSec Medical announced that it has licensed a CAR-T product from Dana-Farber Cancer Institute, specifically from The Marasco Laboratory.

Zacks Investment Research - 1 year ago

OncoSec Medical (ONCS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

About ONCS

OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and adva... [Read more...]

Industry
Biotechnology
Founded
2008
CEO
Daniel O'Connor
Employees
42
Stock Exchange
NASDAQ
Ticker Symbol
ONCS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for ONCS stock is "Strong Buy." The 12-month stock price forecast is 8.13, which is an increase of 13.23% from the latest price.

Price Target
$8.13
(13.23% upside)
Analyst Consensus: Strong Buy